KINGSEY FALLS, QC, May 8, 2025
KINGSEY FALLS, QC, May 8, 2025 /PRNewswire/ - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended March 31, 2025.
Q1 2025 Highlights
Hugues Simon, President and CEO, commented: "Our first quarter performance was driven by lower volumes across our businesses as uncertainty regarding tariffs led to a deterioration in consumer and business sentiment beginning in mid-February, resulting in lower sales and profitability levels sequentially. Results were similarly impacted by usual higher seasonal energy costs, increased operational costs due to lower production, and higher transportation costs. Offsetting these factors were favourable average selling prices and raw material costs across our businesses. Broadly, the depreciation of the Canadian dollar benefited quarterly results."
Discussing near-term outlook, Mr. Simon commented, "We are expecting stronger second quarter results. The sequential improvement in packaging will reflect benefits from the implementation of previously announced price increases. We expect improved tissue performance to be driven by volume growth, with positive retail tissue trends and a pick up in Away-from-Home, along with pricing initiatives, the benefits of which are expected to mitigate higher raw material costs. Broadly, continued uncertainty in the macro-economic environment may impact future demand levels across North America and our outlook."
| 1 | Some information represents non-IFRS Accounting Standards Financial measures, other financial measures or non-IFRS Accounting Standards ratios which are not standardized under IFRS Accounting Standards and therefore might not be comparable to similar financial measures disclosed by other corporations. Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation. |
Financial Summary
Selected consolidated information
| (in millions of Canadian dollars, except amounts per common share) (unaudited) | Q1 2025 | Q4 2024 | Q1 2024 |
| | | | |
| Sales | 1,154 | 1,211 | 1,109 |
| As Reported | | | |
| Operating income | 50 | 16 | 9 |
| Net earnings (loss) | 7 | (13) | (20) |
| per common share (basic) | $0.07 | ($0.13) | ($0.20) |
| Adjusted1 | | | |
| Earnings before interest, taxes, depreciation and amortization (EBITDA (A)) | 125 | 146 | 103 |
| Net earnings (loss) | 13 | 25 | — |
| per common share (basic) | $0.13 | $0.25 | $— |
| Margin (EBITDA (A) / Sales) | 10.8 % | 12.1 % | 9.3 % |
| Net debt1 | 2,216 | 2,096 | 2,020 |
| Net debt / EBITDA (A) ratio1 | 4.2x | 4.2x | 3.8x |
Segmented sales
| (in millions of Canadian dollars) (unaudited) | Q1 2025 | Q4 2024 | Q1 2024 |
| | | | |
| Packaging Products | 762 | 782 | 709 |
| Tissue Papers | 364 | 394 | 367 |
| Inter-segment sales, Corporate, Recovery and Recycling activities | 28 | 35 | 33 |
| Sales | 1,154 | 1,211 | 1,109 |
Segmented operating income (loss)
| (in millions of Canadian dollars) (unaudited) | Q1 2025 | Q4 2024 | Q1 2024 |
| | | | |
| Packaging Products | 60 | 58 | 12 |
| Tissue Papers | 24 | 4 | 31 |
| Corporate, Recovery and Recycling activities | (34) | (46) | (34) |
| Operating income | 50 | 16 | 9 |
Segmented EBITDA (A)1
| (in millions of Canadian dollars) (unaudited) | Q1 2025 | Q4 2024 | Q1 2024 |
| | | | |
| Packaging Products | 109 | 132 | 75 |
| Tissue Papers | 37 | 45 | 50 |
| Corporate, Recovery and Recycling activities | (21) | (31) | (22) |
| EBITDA (A)1 | 125 | 146 | 103 |
| 1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation. |
Analysis of results for the three-month period ended March 31, 2025 (compared to the same period last year)
The Corporation's first quarter sales of $1,154 million increased by $45 million compared with the same period last year. This increase was driven by consolidated net benefits of $47 million from higher selling prices and $45 million from a more favourable foreign exchange. These were partially offset by $48 million from lower volumes.
The first quarter EBITDA (A)1 totaled $125 million, an increase of $22 million, or 21%, from the $103 million generated in the same period last year. This increase was driven by net benefits of $47 million from higher selling prices, mainly in the packaging products segment and a more favourable exchange rate. These were partially offset by net impacts of $10 million from higher production and energy costs and $15 million from lower volumes.
The main specific items, before income taxes, that impacted our first quarter of 2025 operating income and/or net earnings were:
For the three-month period ended March 31, 2025, the Corporation posted net earnings of $7 million, or $0.07 per common share, compared to a net loss of $(20) million, or ($0.20) per common share, in the same period of 2024. On an adjusted basis1, the Corporation posted net earnings of $13 million in the first quarter of 2025, or $0.13 per common share, compared to a net loss of less than a million dollars, or $0.00 per common share, in the same period of 2024.
| 1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation. |
Dividend on common shares and normal course issuer bid
The Board of Directors of Cascades declared a quarterly dividend of $0.12 per common share to be paid on June 5, 2025 to shareholders of record at the close of business on May 22, 2025. This dividend is an "eligible dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the first quarter of 2025, Cascades purchased no common shares for cancellation.
2025 First Quarter Results Conference Call Details
Management will discuss the 2025 first quarter financial results during a conference call today at 9:00 a.m. ET. The call can be accessed by dialing 1-800-990-4777 (international 1-289-819-1299). The conference call, including the investor presentation, will be broadcast live on the Cascades website (www.cascades.com) under the "Investors" section. A replay of the call will be available on the Cascades website and may also be accessed by phone until June 8, 2025 by dialing 1-888-660-6345 (international 1-289-819-1450), access code 38876 #.
Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 9,600 women and men across a network of 68 operating facilities, including 18 Recovery and Recycling facilities which are part of Corporate Activities and joint ventures managed by the Corporation, in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. Certain statements in this release, including statements regarding future results and performance, are forward-looking statements based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for the Corporation's products, increases in raw material costs, fluctuations in selling prices and adverse changes in general market and industry conditions and other factors.
CONSOLIDATED BALANCE SHEETS
| (in millions of Canadian dollars) (unaudited) | March 31, | December 31, |
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | 29 | 27 |
| Accounts receivable | 484 | 469 |
| Current income tax assets | 5 | 4 |
| Inventories | 734 | 685 |
| Current portion of financial assets | 2 | 1 |
| | 1,254 | 1,186 |
| Long-term assets | | |
| Investments in associates and joint ventures | 99 | 97 |
| Property, plant and equipment | 2,826 | 2,847 |
| Intangible assets with finite useful life | 39 | 41 |
| Other assets | 107 | 105 |
| Deferred income tax assets | 219 | 220 |
| Goodwill and other intangible assets with indefinite useful life | 504 | 504 |
| | 5,051 | 5,000 |
| Liabilities and Equity | | |
| Current liabilities | | |
| Bank loans and advances | 4 | 10 |
| Trade and other payables | 689 | 748 |
| Current income tax liabilities | 4 | 2 |
| Current portion of unsecured senior notes of $296 million to be refinanced ($175 million in 2024) | 296 | 175 |
| Current portion of long-term debt | 72 | 67 |
| Current portion of provisions for charges | 47 | 42 |
| Current portion of financial liabilities and other liabilities | 34 | 43 |
| | 1,146 | 1,087 |
| Long-term liabilities | | |
| Long-term debt | 1,873 | 1,871 |
| Provisions for charges | 54 | 58 |
| Other liabilities | 78 | 80 |
| Deferred income tax liabilities | 133 | 133 |
| | 3,284 | 3,229 |
| Equity | | |
| Capital stock | 617 | 616 |
| Contributed surplus | 16 | 16 |
| Retained earnings | 1,013 | 1,019 |
| Accumulated other comprehensive income | 72 | 73 |
| Equity attributable to Shareholders | 1,718 | 1,724 |
| Non-controlling interests | 49 | 47 |
| Total equity | 1,767 | 1,771 |
| | 5,051 | 5,000 |
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
| | For the 3-month periods | |
| (in millions of Canadian dollars, except per common share amounts and number of common shares) (unaudited) | 2025 | 2024 |
| Sales | 1,154 | 1,109 |
| | | |
| Supply chain and logistic | 679 | 668 |
| Wages and employee benefits expenses | 280 | 267 |
| Depreciation and amortization | 69 | 67 |
| Maintenance and repair | 64 | 62 |
| Other operational costs | 6 | 9 |
| Impairment charges | 1 | 2 |
| Other loss | 4 | 3 |
| Restructuring costs | 5 | 23 |
| Unrealized gain on derivative financial instruments | (4) | (1) |
| Operating income | 50 | 9 |
| Financing expense | 36 | 35 |
| Share of results of associates and joint ventures | (3) | (3) |
| Earnings (loss) before income taxes | 17 | (23) |
| Provision for (recovery of) income taxes | 5 | (6) |
| Net earnings (loss) including non-controlling interests for the period | 12 | (17) |
| Net earnings attributable to non-controlling interests | 5 | 3 |
| Net earnings (loss) attributable to Shareholders for the period | 7 | (20) |
| Net earnings (loss) per common share | | |
| Basic | $0.07 | ($0.20) |
| Diluted | $0.07 | ($0.20) |
| Weighted average basic number of common shares outstanding | 100,993,811 | 100,703,177 |
| Weighted average number of diluted common shares | 101,421,656 | 101,216,020 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
| | For the 3-month periods | |
| (in millions of Canadian dollars) (unaudited) | 2025 | 2024 |
| Net earnings (loss) including non-controlling interests for the period | 12 | (17) |
| Other comprehensive income (loss) | | |
| Items that may be reclassified subsequently to earnings | | |
| Translation adjustments | | |
| Change in foreign currency translation of foreign subsidiaries | (41) | 26 |
| Change in foreign currency translation related to net investment hedging activities | 40 | (10) |
| Recovery of income taxes | — | 1 |
| | (1) | 17 |
| Items that are not released to earnings | | |
| Actuarial gain (loss) on employee future benefits | (1) | 7 |
| Provision for income taxes | — | (2) |
| | (1) | 5 |
| Other comprehensive income (loss) | (2) | 22 |
| Comprehensive income including non-controlling interests for the period | 10 | 5 |
| Comprehensive income attributable to non-controlling interests for the period | 5 | 4 |
| Comprehensive income attributable to Shareholders for the period | 5 | 1 |
CONSOLIDATED STATEMENTS OF EQUITY
| | For the 3-month period ended March 31, 2025 | ||||||
| (in millions of Canadian dollars) (unaudited) | CAPITAL STOCK | CONTRIBUTED | RETAINED | ACCUMULATED | TOTAL | NON- | TOTAL |
| Balance - Beginning of period | 616 | 16 | 1,019 | 73 | 1,724 | 47 | 1,771 |
| Comprehensive income (loss) | | | | | | | |
| Net earnings | — | — | 7 | — | 7 | 5 | 12 |
| Other comprehensive income (loss) | — | — | (1) | (1) | (2) | — | (2) |
| | — | — | 6 | (1) | 5 | 5 | 10 |
| Dividends | — | — | (12) | — | (12) | (3) | (15) |
| Issuance of common shares upon exercise of stock options | 1 | — | — | — | 1 | — | 1 |
| Balance - End of period | 617 | 16 | 1,013 | 72 | 1,718 | 49 | 1,767 |
| | | | | | | | |
| | For the 3-month period ended March 31, 2024 | ||||||
| (in millions of Canadian dollars) (unaudited) | CAPITAL STOCK | CONTRIBUTED | RETAINED | ACCUMULATED | TOTAL EQUITY | NON- | TOTAL |
| Balance - Beginning of period | 613 | 15 | 1,096 | 15 | 1,739 | 42 | 1,781 |
| Comprehensive income (loss) | | | | | | | |
| Net earnings (loss) | — | — | (20) | — | (20) | 3 | (17) |
| Other comprehensive income | — | — | 5 | 16 | 21 | 1 | 22 |
| | — | — | (15) | 16 | 1 | 4 | 5 |
| Dividends | — | — | (12) | — | (12) | (3) | (15) |
| Stock options expense | — | 1 | — | — | 1 | — | 1 |
| Acquisition of non-controlling interests | — | — | (2) | — | (2) | (1) | (3) |
| Balance - End of period | 613 | 16 | 1,067 | 31 | 1,727 | 42 | 1,769 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
| | For the 3-month periods | |
| (in millions of Canadian dollars) (unaudited) | 2025 | 2024 |
| Operating activities | | |
| Net earnings (loss) attributable to Shareholders for the period | 7 | (20) |
| Adjustments for: | | |
| Financing expense | 36 | 35 |
| Depreciation and amortization | 69 | 67 |
| Impairment charges | 1 | 2 |
| Other loss | 4 | 3 |
| Restructuring costs | 5 | 23 |
| Unrealized gain on derivative financial instruments | (4) | (1) |
| Provision for (recovery of) income taxes | 5 | (6) |
| Share of results of associates and joint ventures | (3) | (3) |
| Net earnings attributable to non-controlling interests | 5 | 3 |
| Net financing expense paid | (49) | (47) |
| Net income taxes paid | (2) | (5) |
| Dividends received | — | 1 |
| Provisions for charges and other liabilities | (29) | (20) |
| | 45 | 32 |
| Changes in non-cash working capital components | (97) | (70) |
| | (52) | (38) |
| Investing activities | | |
| Payments for property, plant and equipment | (36) | (41) |
| Change in intangible and other assets | 1 | — |
| | (35) | (41) |
| Financing activities | | |
| Bank loans and advances | (6) | 2 |
| Change in credit facilities | 267 | 77 |
| Change in credit facilities without recourse to the Corporation | 1 | 15 |
| Repurchase of unsecured senior notes | (175) | — |
| Increase in delayed draw unsecured term loan credit facility | 36 | — |
| Payments of other long-term debt, including lease obligations (2025 - $18 million for the 3-month period; 2024 - | (19) | (21) |
| Issuance of common shares upon exercise of stock options | 1 | — |
| Dividends paid to non-controlling interests | (3) | (3) |
| Acquisition of non-controlling interests | — | (3) |
| Dividends paid to the Corporation's Shareholders | (12) | (12) |
| | 90 | 55 |
| Net change in cash and cash equivalents during the period | 3 | (24) |
| Currency translation on cash and cash equivalents | (1) | 1 |
| Cash and cash equivalents - Beginning of the period | 27 | 54 |
| Cash and cash equivalents - End of the period | 29 | 31 |
SEGMENTED INFORMATION
In the fourth quarter of 2024, the Corporation announced organizational changes designed to support its strategic growth. These changes involve the combination of the Containerboard and Specialty Products activities into a single operational unit. Since January 2025, the Corporation's operations are managed in two segments: Packaging Products and Tissue Papers. The comparative figures have been restated to conform with the current year's presentation. The accounting policies of the reportable segments are the same as the Corporation's accounting policies described in the most recent Audited Consolidated Financial Statements for the year ended December 31, 2024.
The Corporation's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The Chief Executive Officer has authority for resource allocation and management of the Corporation's performance and is therefore the CODM. The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)). The CODM considers EBITDA (A) to be the best performance measure of the Corporation's activities.
Sales for each segment are prepared on the same basis as those of the Corporation. Inter-segment operations are recorded on the same basis as sales to third parties, which are at fair market value.
EBITDA (A) does not have a standardized meaning under IFRS Accounting Standards; accordingly, it may not be comparable to similarly named measures used by other companies. Investors should not view EBITDA (A) as an alternative measure to, for example, net earnings, or as a measure of operating results, which are IFRS Accounting Standards measures.
Sales by business segment are shown in the following table:
| | SALES | |||||
| For the 3-month periods ended March 31 (in millions of Canadian dollars) (unaudited) | 2025 | 2024 | ||||
| Total | Inter-segment | External | Total | Inter-segment | External | |
| Packaging Products | 762 | (13) | 749 | 709 | (12) | 697 |
| Tissue Papers | 364 | — | 364 | 367 | (1) | 366 |
| Corporate, Recovery and Recycling activities | 73 | (32) | 41 | 82 | (36) | 46 |
| | 1,199 | (45) | 1,154 | 1,158 | (49) | 1,109 |
EBITDA (A) by business segment is reconciled to IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:
| | For the 3-month period ended March 31, 2025 | |||
| (in millions of Canadian dollars) (unaudited) | Packaging | Tissue Papers | Corporate, | Consolidated |
| Operating income (loss) | 60 | 24 | (34) | 50 |
| Depreciation and amortization | 46 | 13 | 10 | 69 |
| Impairment charges | — | — | 1 | 1 |
| Other loss | 4 | — | — | 4 |
| Restructuring costs | 1 | — | 4 | 5 |
| Unrealized gain on derivative financial instruments | (2) | — | (2) | (4) |
| EBITDA (A) | 109 | 37 | (21) | 125 |
| Supply chain and logistic and Wage and employee benefits expenses included in operating income (loss) | 603 | 304 | 52 | 959 |
| | For the 3-month period ended March 31, 2024 | |||
| (in millions of Canadian dollars) (unaudited) | Packaging | Tissue Papers | Corporate, | Consolidated |
| Operating income (loss) | 12 | 31 | (34) | 9 |
| Depreciation and amortization | 43 | 13 | 11 | 67 |
| Impairment charges | 2 | — | — | 2 |
| Other loss | 3 | — | — | 3 |
| Restructuring costs | 16 | 6 | 1 | 23 |
| Unrealized gain on derivative financial instruments | (1) | — | — | (1) |
| EBITDA (A) | 75 | 50 | (22) | 103 |
| Supply chain and logistic and Wage and employee benefits expenses included in operating income (loss) | 589 | 295 | 51 | 935 |
Payments for property, plant and equipment by business segment are shown in the following table:
| | PAYMENTS FOR PROPERTY, PLANT AND EQUIPMENT | |
| | For the 3-month periods | |
| (in millions of Canadian dollars) (unaudited) | 2025 | 2024 |
| Packaging Products | 34 | 14 |
| Tissue Papers | 8 | 8 |
| Corporate, Recovery and Recycling activities | 6 | 6 |
| Total acquisitions | 48 | 28 |
| Right-of-use assets acquisitions and provisions (non-cash) | (24) | (3) |
| | 24 | 25 |
| Acquisitions for property, plant and equipment included in "Trade and other payables" | | |
| Beginning of the period | 32 | 45 |
| End of the period | (20) | (29) |
| Payments for property, plant and equipment | 36 | 41 |
SUPPLEMENTAL INFORMATION ON NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES
SPECIFIC ITEMS
The Corporation incurs some specific items that adversely or positively affect its operating results. We believe it is useful for readers to be aware of these items as they provide additional information to measure performance, compare the Corporation's results between periods, and assess operating results and liquidity, notwithstanding these specific items. Management believes these specific items are not necessarily reflective of the Corporation's underlying business operations in measuring and comparing its performance and analyzing future trends. Our definition of specific items may differ from that of other corporations and some of these items may arise in the future and may reduce the Corporation's available cash.
They include, but are not limited to, charges for (reversals of) impairment of assets, restructuring gains or costs, loss on refinancing and repurchase of long-term debt, some deferred tax asset provisions or reversals, premiums paid on repurchase of long-term debt, gains or losses on the acquisition or sale of a business unit, gains or losses on the share of results of associates and joint ventures, unrealized gains or losses on derivative financial instruments that do not qualify for hedge accounting, unrealized gains or losses on interest rate hedge instruments and option fair value revaluation, foreign exchange gains or losses on long-term debt and financial instruments, fair value revaluation gains or losses on investments, specific items of discontinued operations and other significant items of an unusual, non-cash or non-recurring nature.
RECONCILIATION AND USES OF NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES
To provide more information for evaluating the Corporation's performance, the financial information included in this analysis contains certain data that are not performance measures under IFRS Accounting Standards ("non-IFRS Accounting Standards measures"), which are also calculated on an adjusted basis to exclude specific items. We believe that providing certain key performance and capital measures, as well as non-IFRS Accounting Standards measures, is useful to both Management and investors, as they provide additional information to measure the performance and financial position of the Corporation. This also increases the transparency and clarity of the financial information. The following non-IFRS Accounting Standards measures and other financial measures are used in our financial disclosures:
Non-IFRS Accounting Standards measures
Other financial measures
Non-IFRS Accounting Standards ratios
Non-IFRS Accounting Standards measures and other financial measures are mainly derived from the consolidated financial statements, but do not have meanings prescribed by IFRS Accounting Standards. These measures have limitations as an analytical tool and should not be considered on their own or as a substitute for an analysis of our results as reported under IFRS Accounting Standards. In addition, our definitions of non-IFRS Accounting Standards measures and other financial measures may differ from those of other corporations. Any such modification or reformulation may be significant.
In the fourth quarter of 2024, the Corporation announced organizational changes designed to support its strategic growth. These changes involve the combination of the Containerboard and Specialty Products activities into a single operational unit. Since January 2025, the Corporation's operations are managed in two segments: Packaging Products and Tissue Papers. The comparative figures have been restated to conform with the current year's presentation.
The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)1). The CODM considers EBITDA (A)1 to be the best performance measure of the Corporation's activities.
EBITDA (A)1 by business segment is reconciled to IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:
| | Q1 2025 | |||
| (in millions of Canadian dollars) (unaudited) | Packaging | Tissue Papers | Corporate, | Consolidated |
| Operating income (loss) | 60 | 24 | (34) | 50 |
| Depreciation and amortization | 46 | 13 | 10 | 69 |
| Impairment charges | — | — | 1 | 1 |
| Other loss | 4 | — | — | 4 |
| Restructuring costs | 1 | — | 4 | 5 |
| Unrealized gain on derivative financial instruments | (2) | — | (2) | (4) |
| EBITDA (A)1 | 109 | 37 | (21) | 125 |
| Supply chain and logistic and Wage and employee benefits expenses included in operating income (loss) | 603 | 304 | 52 | 959 |
| | Q4 2024 | |||
| (in millions of Canadian dollars) (unaudited) | Packaging | Tissue Papers | Corporate, | Consolidated |
| Operating income (loss) | 58 | 4 | (46) | 16 |
| Depreciation and amortization | 48 | 14 | 14 | 76 |
| Impairment charges | 32 | 23 | — | 55 |
| Other gain | (7) | — | (1) | (8) |
| Restructuring costs | 2 | 4 | 2 | 8 |
| Unrealized gain on derivative financial instruments | (1) | — | — | (1) |
| EBITDA (A)1 | 132 | 45 | (31) | 146 |
| Supply chain and logistic and Wage and employee benefits expenses included in operating income (loss) | 609 | 325 | 64 | 998 |
| 1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation. |
| | Q1 2024 | |||
| (in millions of Canadian dollars) (unaudited) | Packaging | Tissue Papers | Corporate, | Consolidated |
| Operating income (loss) | 12 | 31 | (34) | 9 |
| Depreciation and amortization | 43 | 13 | 11 | 67 |
| Impairment charges | 2 | — | — | 2 |
| Other loss | 3 | — | — | 3 |
| Restructuring costs | 16 | 6 | 1 | 23 |
| Unrealized gain on derivative financial instruments | (1) | — | — | (1) |
| EBITDA (A)1 | 75 | 50 | (22) | 103 |
| Supply chain and logistic and Wage and employee benefits expenses included in operating income (loss) | 589 | 295 | 51 | 935 |
The following table reconciles net earnings (loss) and net earnings (loss) per common share, as reported, with adjusted net earnings (loss)1 and adjusted net earnings (loss) per common share1:
| (in millions of Canadian dollars, except per common share amounts and number of common shares) (unaudited) | NET EARNINGS (LOSS) | | NET EARNINGS (LOSS) PER COMMON SHARE2 | ||||
| | Q1 2025 | Q4 2024 | Q1 2024 | | Q1 2025 | Q4 2024 | Q1 2024 |
| As reported | 7 | (13) | (20) | | $0.07 | ($0.13) | ($0.20) |
| Specific items: | | | | | | | |
| Impairment charges | 1 | 55 | 2 | | $0.01 | $0.41 | $0.01 |
| Other loss (gain) | 4 | (8) | 3 | | $0.03 | ($0.07) | $0.02 |
| Restructuring costs | 5 | 8 | 23 | | $0.04 | $0.06 | $0.18 |
| Unrealized gain on derivative financial instruments | (4) | (1) | (1) | | ($0.03) | ($0.01) | ($0.01) |
| Unrealized gain on interest rate hedge instrument | — | (2) | (2) | | — | ($0.02) | ($0.01) |
| Foreign exchange loss on long-term debt and financial instruments | — | 1 | 1 | | — | $0.01 | $0.01 |
| Tax effect on specific items, other tax adjustments and attributable to non-controlling interest2 | — | (15) | (6) | | $0.01 | — | — |
| | 6 | 38 | 20 | | $0.06 | $0.38 | $0.20 |
| Adjusted1 | 13 | 25 Für dich aus unserer Redaktion zusammengestelltHinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Weitere Artikel des AutorsThemen im Trend | |||||